Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00393354 |
Study the effect of etoricoxib 60 mg and 90 mg compared to placebo to treat chronic low back pain.
Condition | Intervention | Phase |
---|---|---|
Recurrent Low Back Pain |
Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria :
Exclusion Criteria :
Study ID Numbers: | 2006_548 |
Study First Received: | October 26, 2006 |
Last Updated: | October 27, 2006 |
ClinicalTrials.gov Identifier: | NCT00393354 |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Etoricoxib Neurologic Manifestations Low Back Pain |
Pain Back Pain Recurrence |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Cyclooxygenase Inhibitors Physiological Effects of Drugs Enzyme Inhibitors Pharmacologic Actions Analgesics, Non-Narcotic |
Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |